A Pharmaceuticals (Bulk Drug manufacturing) entity from India is looking to sellout.
Posted By - Investment Banker
Posted date - 25/01/2023
BUSINESS BRIEF
It is a contract manufacturing firm in the Pharmaceutical industry. It owns and operates two state of art WHO-GMP, CGMP and ISO 9001:2008 certified manufacturing plants. Current manufacturing capacities are equivalent to 150 million tablets and capsules per month, along with 1.5 million tubes per month. It owns 50+ formulation brands established over 11 states in India.
Clients:
- Cipla
- MedPlus
- Himalaya
- Ajanta
- Biological E limited
Note: The Company has stopped operations in 2022
Proposal
Industry
Pharmaceuticals
Sub Industry
Bulk Drug manufacturing
Deal Size
INR 95 - 100 Cr
Motives For Sellout
Strategic Realignment
Management is open to continue with the business for handholding the new investor/buyers
Business Operation Information
Industry
Pharmaceuticals
Sub-Industry
Bulk Drug manufacturing
Division
Division`s Buyers/Customers
Financial Information |
2020 (in Cr) | 2021 (in Cr) | 2022 (in Cr) | 2023 (in Cr) |
|---|---|---|---|---|
Sales |
INR 38.9 Cr | INR 48.7 Cr | N.D | N.D |
EBITDA |
N.D | N.D | N.D | N.D |
PAT |
N.D | N.D | N.D | N.D |
TOTAL DEBT |
N.D | N.D | N.D | N.D |
